Treatment options for patients with severe COVID-19.

IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Global health & medicine Pub Date : 2023-04-30 DOI:10.35772/ghm.2023.01024
Momoko Morishita, Masayuki Hojo
{"title":"Treatment options for patients with severe COVID-19.","authors":"Momoko Morishita,&nbsp;Masayuki Hojo","doi":"10.35772/ghm.2023.01024","DOIUrl":null,"url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) pandemic has affected the world for over 3 years. Treatment options have improved substantially during this period, including antiviral drugs, antibody drugs, immune-based agents, and vaccination. While these improvements have reduced mortality rates in patients with COVID-19, some patients still develop severe illness. In this review, we aimed to provide an overview of treatments for patients with severe COVID-19 from study reports and clinical experience. We discussed the treatments from two perspectives: respiratory care and drug treatments. In the respiratory care section, we discussed the usefulness of high-flow nasal cannula therapy and non-invasive ventilation as an alternative to invasive ventilation. In the drug treatments section, we focused on three classes for severe COVID-19 treatment: antiviral drugs, immune-based agents, and anticoagulation therapy. We did not discuss antibody drugs and vaccination, as they are not used for severe COVID-19 treatment.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"5 2","pages":"99-105"},"PeriodicalIF":1.9000,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130548/pdf/ghm-5-2-99.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global health & medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35772/ghm.2023.01024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 1

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has affected the world for over 3 years. Treatment options have improved substantially during this period, including antiviral drugs, antibody drugs, immune-based agents, and vaccination. While these improvements have reduced mortality rates in patients with COVID-19, some patients still develop severe illness. In this review, we aimed to provide an overview of treatments for patients with severe COVID-19 from study reports and clinical experience. We discussed the treatments from two perspectives: respiratory care and drug treatments. In the respiratory care section, we discussed the usefulness of high-flow nasal cannula therapy and non-invasive ventilation as an alternative to invasive ventilation. In the drug treatments section, we focused on three classes for severe COVID-19 treatment: antiviral drugs, immune-based agents, and anticoagulation therapy. We did not discuss antibody drugs and vaccination, as they are not used for severe COVID-19 treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19重症患者的治疗方案。
2019冠状病毒病(COVID-19)大流行已影响全球三年多。在此期间,治疗方案有了显著改善,包括抗病毒药物、抗体药物、免疫制剂和疫苗接种。虽然这些改善降低了COVID-19患者的死亡率,但一些患者仍会患上严重疾病。在这篇综述中,我们旨在从研究报告和临床经验中概述重症COVID-19患者的治疗方法。我们从呼吸护理和药物治疗两方面讨论了治疗方法。在呼吸护理部分,我们讨论了高流量鼻插管治疗和无创通气作为有创通气的替代方法的有效性。在药物治疗部分,我们重点介绍了COVID-19重症治疗的三类:抗病毒药物、免疫药物和抗凝治疗。我们没有讨论抗体药物和疫苗接种,因为它们不用于严重的COVID-19治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
7.70%
发文量
0
期刊最新文献
Advances in HIV management and challenges in Japan: Current situation of pre-exposure prophylaxis in Tokyo. Analysis of tumor infiltrating immune cells in Kaposi sarcoma lesions discovers shifts in macrophage populations. Changes in epidemiological and treatment-related characteristics among newly reported HIV/AIDS cases in an urban area in Shanghai, China from 2001 to 2019: A population-based retrospective study. Exploration of PrEP/PEP service delivery model in China: A pilot in eastern, central and western region. Identification of new circulating recombinant form of HIV-1 CRF139_02B in Japan, and search for the origin.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1